NASDAQ:IVVD Invivyd (IVVD) Stock Forecast, Price & News $1.30 -0.05 (-3.70%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$1.27▼$1.3550-Day Range$1.08▼$1.8052-Week Range$1.03▼$4.90Volume200,309 shsAverage Volume226,420 shsMarket Capitalization$142.32 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Invivyd MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside130.8% Upside$3.00 Price TargetShort InterestBearish8.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.35) to ($0.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.46 out of 5 starsMedical Sector915th out of 987 stocksBiological Products, Except Diagnostic Industry153rd out of 159 stocks 3.0 Analyst's Opinion Consensus RatingInvivyd has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Invivyd has a forecasted upside of 130.8% from its current price of $1.30.Amount of Analyst CoverageInvivyd has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.19% of the float of Invivyd has been sold short.Short Interest Ratio / Days to CoverInvivyd has a short interest ratio ("days to cover") of 14, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldInvivyd does not currently pay a dividend.Dividend GrowthInvivyd does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IVVD. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Invivyd this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for IVVD on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Invivyd insiders have not sold or bought any company stock.Percentage Held by Insiders19.10% of the stock of Invivyd is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.89% of the stock of Invivyd is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Invivyd are expected to grow in the coming year, from ($1.35) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invivyd is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invivyd is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvivyd has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Invivyd (NASDAQ:IVVD) StockInvivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.Read More Receive IVVD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter. Email Address IVVD Stock News HeadlinesMay 23, 2023 | finance.yahoo.comIs Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?May 19, 2023 | americanbankingnews.comQ2 2023 Earnings Estimate for Invivyd, Inc. (NASDAQ:IVVD) Issued By HC WainwrightJune 9, 2023 | Vector Vest (Ad)Free Stock Analysis Report: Get Buy, Sell, or Hold RecommendationGet a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. May 18, 2023 | americanbankingnews.comQ4 2024 EPS Estimates for Invivyd, Inc. Decreased by HC Wainwright (NASDAQ:IVVD)May 13, 2023 | americanbankingnews.comHC Wainwright Weighs in on Invivyd, Inc.'s Q1 2024 Earnings (NASDAQ:IVVD)May 12, 2023 | marketwatch.comInvivyd Reports First Quarter 2023 Financial Results and Business HighlightsMay 11, 2023 | msn.comInvivyd: Q1 Earnings InsightsMay 11, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Esperion (ESPR), Invivyd (IVVD)June 9, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 10, 2023 | msn.com4IVVD : Earnings Preview: InvivydMay 4, 2023 | finance.yahoo.comInvivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business HighlightsMay 1, 2023 | americanbankingnews.comHC Wainwright Initiates Coverage on Invivyd (NASDAQ:IVVD)April 25, 2023 | benzinga.comInvivyd to Participate at H.C. Wainwright's BioConnect Investor ConferenceApril 25, 2023 | finance.yahoo.comInvivyd to Participate at H.C. Wainwright’s BioConnect Investor ConferenceApril 25, 2023 | finance.yahoo.comInvivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial UpdateApril 14, 2023 | finance.yahoo.comAfter Plunging -26.71% in 4 Weeks, Here's Why the Trend Might Reverse for Invivyd, Inc. (IVVD)March 31, 2023 | benzinga.comINVIVYD DEADLINE ALERT: Bragar Eagel & Squire...March 30, 2023 | finance.yahoo.comInvivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19March 30, 2023 | americanbankingnews.comInvivyd (NASDAQ:IVVD) Price Target Lowered to $1.00 at Morgan StanleyMarch 29, 2023 | prnewswire.comIVVD FINAL DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IVVD, ADGIMarch 29, 2023 | benzinga.comIVVD LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of INVIVYD, INC. F/K/A ADAGIO THERAPEUTICS, INC. ShareholdersMarch 29, 2023 | benzinga.comIVVD LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Invivyd, Inc. f/k/a Adagio Therapeutics, Inc.March 28, 2023 | finance.yahoo.comInvivyd, Inc. (NASDAQ:IVVD) Q4 2022 Earnings Call TranscriptMarch 24, 2023 | benzinga.comInvivyd, Inc. (IVVD) Investor Alert: Robbins LLP Reminds Investors of Pending Lead Plaintiff Deadline in Invivyd, Inc. Class ActionMarch 24, 2023 | benzinga.comInvivyd Reports Full Year 2022 Financial Results and Business HighlightsMarch 22, 2023 | benzinga.comInvivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19March 17, 2023 | prnewswire.comIVVD SHAREHOLDER ALERT: Jakubowitz Law Reminds Invivyd Shareholders of a Lead Plaintiff Deadline of April 3, 2023See More Headlines IVVD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IVVD Company Calendar Last Earnings3/23/2023Today6/09/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IVVD CUSIPN/A CIK1832038 Webadagiotx.com Phone781-819-0080FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+129.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-241,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.74% Return on Assets-42.85% Debt Debt-to-Equity RatioN/A Current Ratio15.62 Quick Ratio15.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.27 per share Price / Book0.40Miscellaneous Outstanding Shares109,480,000Free Float88,571,000Market Cap$143.42 million OptionableOptionable Beta0.11 Key ExecutivesMr. David Hering M.B.A. (Age 47)CEO & Director Comp: $453.76kMs. Jill Andersen J.D. (Age 49)Chief Legal Officer & Corp. Sec. Comp: $580.12kMs. Laura Walker Ph.D. (Age 37)Co-Founder & Chief Scientific Officer Mr. Frederick W. Driscoll (Age 71)Interim CFO, Principal Financial Officer & Principal Accounting Officer Mr. Jeremy GowlerChief Operating & Commercial OfficerDr. Rebecca Dabora Ph.D. (Age 63)Chief Technology & Manufacturing Officer Kyra Rosow FairclothVP of Gov. Affairs, Advocacy & Corp. CommunicationDr. Peter C. Schmidt M.D.M.Sc., Chief Medical OfficerMore ExecutivesKey CompetitorsSorrento TherapeuticsNASDAQ:SRNEINmune BioNASDAQ:INMBAtara BiotherapeuticsNASDAQ:ATRAAdaptimmune TherapeuticsNASDAQ:ADAPAdverum BiotechnologiesNASDAQ:ADVMView All CompetitorsInstitutional OwnershipPrelude Capital Management LLCBought 25,308 shares on 6/1/2023Ownership: 0.023%JPMorgan Chase & Co.Bought 325,587 shares on 5/18/2023Ownership: 0.297%New York State Common Retirement FundBought 31,147 shares on 5/18/2023Ownership: 0.028%Susquehanna International Group LLPBought 52,061 shares on 5/16/2023Ownership: 0.048%Jane Street Group LLCBought 26,996 shares on 5/16/2023Ownership: 0.025%View All Institutional Transactions IVVD Stock - Frequently Asked Questions Should I buy or sell Invivyd stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Invivyd in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IVVD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IVVD, but not buy additional shares or sell existing shares. View IVVD analyst ratings or view top-rated stocks. What is Invivyd's stock price forecast for 2023? 2 analysts have issued 12-month target prices for Invivyd's shares. Their IVVD share price forecasts range from $1.00 to $5.00. On average, they predict the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 129.0% from the stock's current price. View analysts price targets for IVVD or view top-rated stocks among Wall Street analysts. How have IVVD shares performed in 2023? Invivyd's stock was trading at $1.50 at the start of the year. Since then, IVVD shares have decreased by 12.7% and is now trading at $1.31. View the best growth stocks for 2023 here. When is Invivyd's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our IVVD earnings forecast. How were Invivyd's earnings last quarter? Invivyd, Inc. (NASDAQ:IVVD) posted its quarterly earnings results on Thursday, March, 23rd. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by $0.02. What ETF holds Invivyd's stock ? ETFMG Treatments Testing and Advancements ETF holds 35,155 shares of IVVD stock, representing 0.23% of its portfolio. What is Invivyd's stock symbol? Invivyd trades on the NASDAQ under the ticker symbol "IVVD." Who are Invivyd's major shareholders? Invivyd's stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (12.76%), Alphabet Inc. (5.20%), BlackRock Inc. (3.45%), Slate Path Capital LP (3.42%), Bain Capital Life Sciences Investors LLC (1.77%) and Maverick Capital Ltd. (1.73%). How do I buy shares of Invivyd? Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Invivyd's stock price today? One share of IVVD stock can currently be purchased for approximately $1.31. How much money does Invivyd make? Invivyd (NASDAQ:IVVD) has a market capitalization of $143.42 million. The company earns $-241,320,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. How can I contact Invivyd? Invivyd's mailing address is 1601 TRAPELO ROAD SUITE 178, WALTHAM MA, 02451. The official website for the company is adagiotx.com. The company can be reached via phone at 781-819-0080 or via email at investors@adagiotx.com. This page (NASDAQ:IVVD) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.